跳至主要内容
临床试验/NCT04135248
NCT04135248Unknown不适用

A Randomized Control Trial in People With Type 1 Diabetes Mellitus Who Will Fast Ramadan: Does Insulin Timing and Dose Matter?

Dasman Diabetes Institute1 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2019年4月18日最近更新:
适应症

试验速览

阶段
不适用
入组人数
50
试验地点
1
主要终点
Rate of self-reported hypoglycaemia

研究概览

简要总结

Fasting Ramadan is one of the five pillars of Islam and requested only from healthy adults to abstain from eating and drinking from sunrise to sunset. People with type 1 diabetes mellitus (TIDM) are exempted from fasting, as their chronic condition could be adversely affected by fasting. Nevertheless, many insist on fasting and it has been experienced and advocated that with proper education and follow-up with health care providers, people with uncomplicated T1DM could safely fast Ramadan.

Adopted IDF-DAR guidelines for people with diabetes planning to fast Ramadan are available but are based on opinions and largely untested. These current guidelines recommend a significant reduction in insulin doses and a change of the timing of basal insulin and highlight the increased risk of hypoglycemia. Our local DAFNE patient's experience with fasting during the past years points towards no significant changes in insulin timing with minor reductions of insulin without a significant increase in the risk of hypoglycemia. There is no randomized control trial to test the efficacy of the IDF-DAR guidelines specifically looking at changing basal insulin timing This study aims to assess whether insulin doses require reduction and change of timing during Ramadan. We aim to compare the effectiveness and safety of two management strategies. This will help to provide robust guidelines to help both health care professionals and people with type 1 diabetes

详细描述

INTRODUCTION/BACKGROUND

Diabetes and Ramadan (DAR) and IDF international collaboration created the IDF-DAR guidelines which include the practical recommendations for HCP to better manage people with diabetes who plan to fast Ramadan. The National Institute for Health and Clinical Excellence has recommended implementation of structured education programs to help individuals enhance their knowledge about diabetes and improve their management techniques. The educational program needs to ensure that patients can cope with specific situations such as exercise, illness which should extend to religious fasting.

We have developed and adopted a 5-day educational program widely used in the UK for delivery in Kuwait. The course trains adults with Type 1 Diabetes in the UK to manage their condition more effectively using multiple injections. As part of our course, DAFNE graduates receive yearly Ramadan diabetes educational specific session (separate from the main 5-day course) and all DAFNE graduates are invited. During the 6 hours session, we seek patients' views, willingness to fast and introduced to the specific food that commonly consumed during Ramadan. Previous personal experiences of fasting and problems encountered are collected. Patients who are intending to fast and whom we deem safe to undertake this, receive clear and practical guidance on safe fasting during Ramadan.

Current Gaps in the Literature

Most intervention studies up to date have been performed in controlled conditions, using a small number of participants and with a short duration of intervention, ie not closely related to real-life. The variability of insulin regimens, dietary patterns and physical activity levels and the complexity of ways in which they are tested make it difficult to identify the individual effects of each component on diabetes outcomes. As a result, further research is needed to help expand the currently available knowledge regarding the management of diabetes and its associated complications when fasting during Ramadan. We believe that large, randomized, controlled intervention trials are necessary to broaden our understanding of the implications of fasting and evaluate guidance without bias. Further research into the effect of fasting during Ramadan on both high (measured by SMBG and HbA1C) and low glucose (measured by the incidence of hypoglycemia) is required. Robust evaluation of evidence-based guidelines will lead to useful practical assistance for patients who can fulfill religious obligations despite the additional burden of insulin-treated diabetes. This pilot study builds on an educational program, DAFNE which includes many of the elements of flexible eating and insulin dose adjustment which should permit patients to fast safely.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
21 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • T1DM for 12 months or more
  • Age >21 years old
  • Current user of FSL and plan to use it during Ramadan
  • HbA1C <10%
  • Planning to fast Ramadan
  • People with T1DM on insulin pump

排除标准

  • Any significant diabetes-related complications including, but not limited to
  • Any recent episode of severe hypoglycemia in the preceding 12 months
  • Any recent DKA in the preceding 12 months
  • Diabetic nephropathy with eGFR <60ml/minute/1.73m2
  • Diabetic retinopathy ≥R2, ≥M1
  • Peripheral neuropathy
  • Active or recent foot ulcers
  • HbA1c greater than 10%.
  • Hypoglycaemia unawareness
  • Pregnancy or plannig for pregnancy over the duration of the study
  • Breast feeding
  • Active malignancy
  • Uncontrolled thyroid disorders
  • Not able to attend study visits
  • Not able or not willing to give written informed consent
  • Not DAFNE graduates

结局指标

主要结局

Rate of self-reported hypoglycaemia

时间窗: 30 days

The data of self- reported hypoglycaemic episode will be collected daily basis by using telecommunication and whatsapp massage.

Percentage time spent in glucose range 4-10mmol/L

时间窗: 30 days

FreeStlye libre software will be used to extract reports and data export readings of FSL readers. Data will be collected during the whole month of Ramadan fasting for the outcome measure.

次要结局

  • Percentage time at the glucose level <4mmol/L or >10mmol/L(30 days)
  • Number of days needed to break the fast(30 days)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Dr. Ebaa Al Ozairi

Chief Medical Officer

Dasman Diabetes Institute

研究点 (1)

Loading locations...

相似试验